PACBODY Trademark

Trademark Overview

On Thursday, October 17, 2019, a trademark application was filed for PACBODY with the United States Patent and Trademark Office. The USPTO has given the PACBODY trademark a serial number of 88658020. The federal status of this trademark filing is REGISTERED as of Tuesday, June 13, 2023. This trademark is owned by Phanes Therapeutics, Inc.. The PACBODY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services and research and development activities relating thereto, namely, antibody research and design; Providing recombinant antibody technology platform in the nature of research and development of monospecific, bispecific and multi-specific antibodies or fragments and the development of pharmaceutical products based on monospecific, bispecific and multi-specific antibodies or fragments; Research and development services in the field of antibodies; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; medical and scientific research in the field of cancer treatment and diagnosis; technical research in the field of pharmaceutical studies; research on the subject of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development; pharmaceutical product development; product developability testing, namely, pharmaceutical antibody evaluation; developm...
pacbody

General Information

Serial Number88658020
Word MarkPACBODY
Filing DateThursday, October 17, 2019
Status700 - REGISTERED
Status DateTuesday, June 13, 2023
Registration Number7080972
Registration DateTuesday, June 13, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 9, 2020

Trademark Statements

Pseudo MarkPACK BODY
Goods and ServicesScientific and technological services and research and development activities relating thereto, namely, antibody research and design; Providing recombinant antibody technology platform in the nature of research and development of monospecific, bispecific and multi-specific antibodies or fragments and the development of pharmaceutical products based on monospecific, bispecific and multi-specific antibodies or fragments; Research and development services in the field of antibodies; research and development of pharmaceuticals for the treatment of age-related diseases and cancer; medical and scientific research in the field of cancer treatment and diagnosis; technical research in the field of pharmaceutical studies; research on the subject of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development; pharmaceutical product development; product developability testing, namely, pharmaceutical antibody evaluation; development of pharmaceutical preparations and medicines; product design-based functionality testing, namely, conducting early evaluations in the field of new pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; chemical, biochemical, biological and bacteriological research and analysis; biological research; scientific study, research and development in the fields of medicine, the prevention, treatment and management of illness, health care delivery; technology research in the field of pharmaceutical research and development; medical research; medical laboratories

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 21, 2019
Primary Code042
First Use Anywhere DateSaturday, December 31, 2022
First Use In Commerce DateThursday, March 16, 2023

Trademark Owner History

Party NamePhanes Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NamePhanes Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NamePhanes Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Tuesday, June 13, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, June 13, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, May 11, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, May 10, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, April 7, 2023STATEMENT OF USE PROCESSING COMPLETE
Tuesday, March 21, 2023USE AMENDMENT FILED
Thursday, April 6, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 21, 2023TEAS STATEMENT OF USE RECEIVED
Friday, August 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 24, 2022SOU EXTENSION 4 GRANTED
Wednesday, August 24, 2022SOU EXTENSION 4 FILED
Wednesday, August 24, 2022TEAS EXTENSION RECEIVED
Wednesday, March 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 28, 2022SOU EXTENSION 3 GRANTED
Monday, March 28, 2022SOU EXTENSION 3 FILED
Monday, March 28, 2022TEAS EXTENSION RECEIVED
Tuesday, July 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 9, 2021SOU EXTENSION 2 GRANTED
Friday, July 9, 2021SOU EXTENSION 2 FILED
Friday, July 9, 2021TEAS EXTENSION RECEIVED
Wednesday, March 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 1, 2021SOU EXTENSION 1 GRANTED
Monday, March 1, 2021SOU EXTENSION 1 FILED
Monday, March 1, 2021TEAS EXTENSION RECEIVED
Tuesday, February 23, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, February 23, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, February 23, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 23, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 29, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 19, 2020EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, July 8, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, June 9, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 9, 2020PUBLISHED FOR OPPOSITION
Wednesday, May 20, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 30, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 30, 2020EXAMINER'S AMENDMENT ENTERED
Thursday, April 30, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, April 30, 2020EXAMINERS AMENDMENT E-MAILED
Thursday, April 30, 2020EXAMINERS AMENDMENT -WRITTEN
Tuesday, April 14, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, April 14, 2020FINAL REFUSAL E-MAILED
Tuesday, April 14, 2020FINAL REFUSAL WRITTEN
Tuesday, March 24, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 23, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 23, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 23, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 23, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 23, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 23, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, March 23, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 28, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 28, 2020NON-FINAL ACTION E-MAILED
Tuesday, January 28, 2020NON-FINAL ACTION WRITTEN
Thursday, January 23, 2020ASSIGNED TO EXAMINER
Monday, October 21, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 21, 2019NEW APPLICATION ENTERED

Related Keywords

pacbody research development pharmaceutical antibody antibodies field specific multi bispecific product